Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001209191-21-004466

Chief Executive Officer sold 20,000 shares at an average $213.67 ($4,273,311)

  • Chief Executive Officer acquired 20,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Kulkarni Samarth Chief Executive Officer 2021-01-15 Option exercise +20,000 $1.81 $36,200 202,989 D
Kulkarni Samarth Chief Executive Officer 2021-01-15 Sale −3,140 $211.83 $665,146 199,849 D
Kulkarni Samarth Chief Executive Officer 2021-01-15 Sale −6,525 $212.75 $1,388,194 193,324 D
Kulkarni Samarth Chief Executive Officer 2021-01-15 Sale −5,623 $213.71 $1,201,691 187,701 D
Kulkarni Samarth Chief Executive Officer 2021-01-15 Sale −1,700 $214.68 $364,956 186,001 D
Kulkarni Samarth Chief Executive Officer 2021-01-15 Sale −1,708 $216.50 $369,782 184,293 D
Kulkarni Samarth Chief Executive Officer 2021-01-15 Sale −1,304 $217.44 $283,542 182,989 D
Derivatives
Kulkarni Samarth Chief Executive Officer 2021-01-15 Option exercise · Stock Option (Right to Buy) −20,000 108,983 D
Open-market sales · 20,000 sh · avg $213.67 · $4,273,311
Loading xslF345X03/doc4.xml…